A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel – Carboplatin - Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
To see how safe and effective four doses of the experimental drug oregovomab is given at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.
DiagnosisPatients with newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease.
Newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
Completed debulking surgery (both primary and interval allowed).
ECOG 0-1. No mucinous or low-grade adeno allowed.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Adjuvant chemo (3 or 6 cycles depending on primary or interval debulking) + Oregovomab/Placebo
For more information, visit Clinicaltrials.gov